SCHEMBL2368632

SCHEMBL2368632

O=C(N1CCc2ccc(Cl)c(NC(c3ccccc3)c3ccncc3)c2CC1)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.39
ESR2 Q92731 5/20 0.39
GPR142 Q7Z601 2/20 0.38
KDM4C Q9H3R0 1/20 0.35
CACNA2D1 P54289 1/20 0.33
CACNA1B Q00975 1/20 0.33
CACNB1 Q02641 1/20 0.33
CACNA1C Q13936 1/20 0.33
ACKR3 P25106 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TSHR P16473 1/20 0.33
PRCP P42785 1/20 0.33
USP2 O75604 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
CHRM1 P11229 1/20 0.32
KMT2A Q03164 1/20 0.32
P2RX7 Q99572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL506602 0.87 ESR1 (0.41) ESR1ESR2GPR142CYP2C9
SCHEMBL507134 0.85 ESR1 (0.43) ESR1ESR2ACKR3KDM4EKMT2A
SCHEMBL507135 0.85 ESR1 (0.43) ESR1ESR2ACKR3KDM4EKMT2A
SCHEMBL506880 0.77 ESR1 (0.42) ESR1ESR2ACKR3
SCHEMBL507438 0.77 ESR1 (0.43) ESR1ESR2
SCHEMBL507772 0.77 ESR1 (0.41) ESR1ESR2ACKR3
SCHEMBL508096 0.76 ESR1 (0.42) ESR1ESR2KMT2A
SCHEMBL508097 0.76 ESR1 (0.42) ESR1ESR2KMT2A
SCHEMBL506804 0.76 ESR1 (0.40) ESR1ESR2ACKR3TSHRCYP2D6
SCHEMBL507545 0.75 HTR2C (0.46) ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 ESR1 331/4885ESR2 210/4885GPR142 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.